VTRS Viatris Inc

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights $VTRS $PCRX $GEHC $BHVN $ALEC https://stocktwits.com/news/equity/markets/stocktwits-biotech-dealmaker-viatris-and-ge-healthcare-buy-what-they-can-sell-biohaven-and-alector-sell-rights/cZxThBFRBnn

$VTRS Love the 19 dollar hollar. My question is when are we going to get Teva multiple? Good luck to us longs.

$VTRS Latest analyst update, Oct 21, 2026: JPMorgan kept Neutral and raised its price target on Viatris to 20 USD from 18 USD. Third-party analyst opinion. More details in our $VTRS stock hub. Not investment advice.

Thursday pre-mkt Chat nuggets: $VTRS for $PCRX in the pain space a reminder of the appeal of unsexy areas of drug development $PROF - Playbook setup spiking, but I caution $2.5M of revenue was carried forward from Q2 (supposed to be last week of June) $NKTR - example of extreme swings in sentiment yet thesis intact, POD reversal trade incoming? Real-time Trades Channel, noticing quite a few people paring down to fewer but higher quality holdings to sleep better at night & navigate rough waters $XBI

$VTRS - Viatris targets non-opioid pain leadership with a $1.65 billion Pacira $PCRX (for $36.5/share) deal and two patent-protected U.S. brands. Screenshot of recent headlines for Viatris from Top Tier Newswire:

$VTRS · $PCRX 🤝 Viatris Inc. commenced a tender offer through subsidiary Peach Purchaser Sub Inc. to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share in cash. Selected from hundreds of headlines

$VTRS FDA approved RYZUMVI for presbyopia on Friday, its second indication. The mydriasis version is already the only commercially available FDA-approved product in the US for that use. Approval is not a launch yet though. Viatris said it's still exploring a US partner to commercialize the presbyopia version, so there's no revenue line attached to this one for now.

$VTRS 🏥 Viatris Inc. receives U.S. FDA approval for RYZUMVI for the treatment of presbyopia.

Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus $VTRS $PCRX $KO $DVN $CRGY https://stocktwits.com/news/equity/markets/viatris-pacira-coca-cola-costa-devon-crescent-stocktwits-ma-watch/cZxIb2SRBFZ

$VTRS Viatris is buying Pacira for $36.50 a share in cash, a 44.8% premium that values the company at about 1.65 billion dollars (Reuters, Oct 8). That's roughly 2.4x what Pacira's two pain drugs, Exparel and Zilretta, did in combined 2025 net product sales ($575.1M and $116.6M). Viatris plans to fund it mostly from excess cash, with minimal impact expected on its gross leverage ratio.